ABLYNX : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 27TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 27TH ANNUAL  J.P.
MORGAN HEALTHCARE CONFERENCE


GHENT, Belgium, 12 January 2009 - Ablynx [Euronext Brussels: ABLX], a
pioneer in  the discovery  and development  of Nanobodies®,  a  novel
class of antibody-derived therapeutic proteins, today announced  that
it will webcast its  corporate presentation at  the 27th Annual  J.P.
Morgan Healthcare Conference on Wednesday,  14 January 2009 at  11.00
a.m. PST / 08.00 p.m. CET.

The presentation,  followed by  a Q&A,  will be  hosted by  Dr  Edwin
Moses, CEO and Chairman at Ablynx. This will be webcast live and  may
be accessed on the home page of Ablynx's website at www.ablynx.com. A
replay of the webcast will also be available on the Company's website
for 90 days, by default (until 15 April 2009).

To ensure a timely connection, it is recommended that users  register
at least 10 minutes prior to the scheduled webcast.

                               -ends-

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in  2001 in  Ghent, Belgium,  Ablynx is  a  biopharmaceutical
company focused on  the discovery and  development of Nanobodies®,  a
novel class of therapeutic  proteins based on single-domain  antibody
fragments,  for  a  range  of  serious  and  life-threatening   human
diseases. The  Company  currently  has  over  200  employees.  Ablynx
completed a successful IPO on Euronext Brussels [ABLX] on 7  November
2007.

Ablynx is  developing  a  portfolio  of  Nanobody®-based  therapeutic
programmes  in   a  number   of   major  disease   areas,   including
inflammation,   thrombosis,   oncology   and   Alzheimer's   disease.
Nanobodies® have  been  generated  against more  than  100  different
disease targets. Efficacy data has been  obtained in over 25 in  vivo
models for Nanobodies® against a range of different targets.

Ablynx has an extensive patent  position in the field of  Nanobodies®
for healthcare applications. It has exclusive and worldwide rights to
more  than  50  families  of  granted  patents  and  pending   patent
applications,  including  the  Hamers  patents  covering  the   basic
structure, composition, preparation and uses of Nanobodies®.

For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t:   [phone]
f:   [phone]
e:  [e-mail]

Ablynx:
Dr. Edwin Moses
Chairman and CEO
t:   [phone]
m: [phone] / [phone]
e:  [e-mail]

Eva-Lotta Allan
Chief Business Officer
t:   [phone]
m: [phone] / [phone]
e:  [e-mail]


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.
http://hugin.info/137912/R/1281672/286660.pdf


Copyright © Hugin AS 2009. All rights reserved.